Evidence map›Paper›PMID 39433730›Full record

ArticleBlood cancer journal2024

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry and 4 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rakesh PopatNIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0001-6553-4618
Bradley AugustsonSir Charles Gairdner Hospital and Linear Clinical Research, Perth, WA, Australia.
Mercedes GironellaDepartment of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8106-8909
Cindy LeeRoyal Adelaide Hospital, Adelaide, SA, Australia.
Paul CannellDepartment of Haematology, Fiona Stanley Hospital, Perth, WA, Australia.
Nashita PatelGSK, London, UK.
Ravi S KasinathanGSK, Upper Providence, PA, USA.
Rachel RogersGSK, Upper Providence, PA, USA.
Mehreen ShaikhGSK, London, UK.
Amy CurryGSK, Durham, NC, USA.
Fernando CarreñoGSK, Upper Providence, PA, USA.
Sumita Roy-GhantaGSK, Upper Providence, PA, USA.
Joanna OpalinskaGSK, Upper Providence, PA, USA.
Hang QuachUniversity of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia. HANG.QUACH@svha.org.au.ORCID http://orcid.org/0000-0002-4796-3352

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39433730
PMCPMC11494064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.